Ultrasound Cycloplasty Offers New Hope for Glaucoma Pressure Control
Glaucoma can quietly damage vision long before a person notices a problem. Because the condition may progress without obvious early symptoms, regular eye examinations and effective pressure management are essential for protecting the optic nerve.
Research published on October 15, 2026, highlights ultrasound cycloplasty as a potential option for patients whose glaucoma remains difficult to control despite intensive medical treatment. The one-year study from Northwest China found a substantial reduction in intraocular pressure, alongside improvements in daily pressure fluctuations and eye discomfort.
The research, published in Frontiers in Medicine, examined 24 patients with 30 affected eyes. Although the results are encouraging, the study was relatively small and conducted at a single center, so its findings should not be interpreted as proof that the procedure will work equally well for every patient.
How Ultrasound Cycloplasty Works Inside the Eye
Intraocular pressure, commonly abbreviated as IOP, refers to the pressure inside the eye. It is influenced by the production and drainage of aqueous humor, the clear fluid that helps maintain the eye’s structure and supplies nutrients to certain tissues.
When pressure becomes too high for an individual eye, the optic nerve can sustain damage. Glaucoma treatment aims to lower pressure sufficiently to reduce the risk of further injury, although the appropriate target depends on the patient’s condition and disease progression.
Ultrasound cycloplasty, also known as ultrasound cycloplasty (UCP), uses high-intensity focused ultrasound to target the ciliary body, a structure involved in producing aqueous humor. The treatment delivers concentrated acoustic energy to selected areas, reducing fluid production and helping lower the pressure inside the eye.
In the 2026 study, the treatment used a tailored approach based on the patient’s starting pressure. Each treated sector received ultrasound energy for 22 seconds at 2.3 watts, equivalent to 50.65 joules per sector.
The number of treated sectors was adjusted according to baseline pressure: six sectors for pressures below 30 mmHg, eight for pressures of 30 mmHg or higher, and ten for pressures of 40 mmHg or higher. The procedure typically took three to five minutes, according to the report.
This is a specialized ophthalmic procedure, not a home treatment or a substitute for prescribed glaucoma medication without medical supervision. Patient selection, treatment planning, and follow-up require an experienced eye specialist.
What the One-Year Glaucoma Study Discovered
The study included patients with several forms of glaucoma: primary angle-closure glaucoma, primary open-angle glaucoma, neovascular glaucoma, and secondary glaucoma associated with other eye diseases. Their pressure had not been adequately controlled despite maximal medical therapy.
Across the 30 treated eyes, the median intraocular pressure before treatment was 40.5 mmHg. At the one-year assessment, the median had fallen to 12 mmHg, representing a 59.91% reduction.
The results differed across glaucoma subtypes. Patients with primary angle-closure glaucoma experienced a 66.12% reduction in pressure at one year, and the reported surgical success rate for this group reached 96.67% at final follow-up.
Patients with secondary glaucoma and neovascular glaucoma also experienced meaningful pressure reductions. However, the strongest effects in these groups appeared later, between six months and one year, rather than immediately after treatment.
These distinctions matter because glaucoma is not a single uniform disease. Its underlying cause, the condition of the optic nerve, existing damage, and the patient’s response to earlier treatments can all influence the outcome of a procedure.
The investigators also found that higher starting pressure was associated with a greater reduction after treatment. The reported Spearman correlation coefficient was 0.641, indicating a positive relationship between baseline pressure and the amount of pressure reduction at one year.
However, this association does not mean that patients with the highest pressures are guaranteed to benefit the most. The findings need confirmation in larger studies involving more patients and a wider range of clinical settings.
Why Stabilizing Eye Pressure Matters Beyond a Single Reading
Eye pressure can vary throughout the day and night. A measurement taken during a routine appointment provides useful information, but it may not capture the full pattern of pressure changes that a patient experiences over 24 hours.
The Northwest China study therefore examined the mean amplitude of intraocular pressure excursion, or MAPE, as an indicator of pressure variability. This measure was used to evaluate changes in pressure fluctuations rather than relying solely on individual readings.
The mean MAPE decreased from 10.6 before treatment to 5.3 one day after the procedure, effectively halving the measured fluctuation. The researchers interpreted this finding as evidence that ultrasound cycloplasty may help make pressure patterns more stable.
For clinicians, monitoring pressure over time can help determine whether treatment is achieving its intended goal. Tonometry measures intraocular pressure, while visual field testing and optical coherence tomography (OCT) can help assess functional vision and structural changes associated with glaucoma.
Pressure reduction is an important treatment objective, but it does not restore optic nerve tissue already lost to glaucoma. Continued monitoring remains necessary even when pressure readings improve.
Safety Findings, Limitations, and Patient Considerations
The study reported several temporary postoperative effects. Conjunctival hyperemia, or redness of the eye, occurred in 86.7% of treated eyes within 24 hours and resolved over the following days.
Anterior chamber inflammation was reported in 46.7% of eyes, while pupillary irregularities occurred in 40%. The report indicated that the pupillary changes stabilized within two weeks.
Importantly, researchers observed no cases of profound hypotony, choroidal detachment, macular edema, or phthisis bulbi during the follow-up period. These findings are reassuring for the patients studied, but they do not establish that serious complications are impossible.
Reported pain scores also declined, from a median of 5 before treatment to 1 at one year. This suggests that some patients experienced lasting relief from eye discomfort, although pain outcomes do not measure the preservation of vision itself.
The authors acknowledged important limitations, including the small sample, the single-center design, and the absence of an adjustment for correlations between two eyes from the same patient when both eyes were included. Larger multicenter studies are needed, particularly to clarify outcomes for patients with neovascular and other difficult-to-treat forms of glaucoma.
When to See an Eye Doctor About Glaucoma
Glaucoma may develop without noticeable symptoms, especially in its early stages. People with a family history of glaucoma, elevated eye pressure, or other recognized risk factors should discuss an appropriate screening schedule with an eye-care professional.
An assessment may include tonometry, examination of the optic nerve, visual field testing, OCT imaging, and gonioscopy, which allows the specialist to examine the drainage angle inside the eye. The tests selected will depend on the patient’s symptoms and clinical history.
Seek urgent medical care if you develop sudden severe eye pain, a red eye accompanied by blurred vision, halos around lights, severe headache, nausea, or vomiting. These symptoms can occur with acute angle-closure glaucoma, which requires immediate assessment.
Patients already receiving glaucoma treatment should not stop eye drops or change their treatment schedule because of encouraging research findings. Any decision about ultrasound cycloplasty should be made with a qualified ophthalmologist after reviewing the potential benefits, risks, and alternatives.
Frequently Asked Questions
Can ultrasound cycloplasty cure glaucoma?
No. The procedure is intended to reduce intraocular pressure and may help control the disease, but it cannot reverse existing optic nerve damage or guarantee that glaucoma will stop progressing.
Does every patient with glaucoma qualify for this procedure?
No. The 2026 study focused on patients whose pressure remained inadequately controlled despite intensive medical treatment. Whether UCP is appropriate depends on the glaucoma subtype, eye health, previous treatments, and specialist assessment.
Does lower eye pressure mean vision will improve?
Not necessarily. Lower pressure can help reduce the risk of additional damage, but established vision loss from glaucoma is generally irreversible. Treatment success must be assessed through continued pressure measurements and appropriate optic nerve and visual function testing.
The next practical step for anyone concerned about glaucoma is to arrange a comprehensive eye examination and discuss individual pressure targets with an ophthalmologist. The findings published in Frontiers in Medicine provide a promising direction for further research, but longer and larger studies are still needed to establish which patients are most likely to benefit from ultrasound cycloplasty.
